000 04561nam a2200373Ia 4500
001 CAH0KE12048PDF
003 BD-DhSAU
005 20151012144310.0
006 m|||||o||d||||||||
007 cr||||
008 120831s2013 fluad sb 001 0 eng d
020 _a9781439846353 (ebook : PDF)
040 _aBD-DhSAU
_cBD-DhSAU
090 _aRM301.27
_b.D47 2013
092 _a615.10724
_bD457
245 0 0 _aDesign and analysis of bridging studies
_h[electronic resource] /
_cedited by Jen-Pei Liu, Shein-Chung Chow, Chin-Fu Hsiao.
260 _aBoca Raton :
_bCRC Press,
_c2013.
300 _axviii, 269 p. :
_bill.
490 1 _aChapman & Hall/CRC biostatistics series
500 _a"A Chapman & Hall book."
504 _aIncludes bibliographical references and index.
505 0 _a1. Bridging diversity : extrapolating foreign data to a new region / Shein-Chung Chow and Chin-Fu Hsiao -- 2. Two-stage designs of bridging studies / Chin-Fu Hsiao ... [et al.] -- 3. Consistency of treatment effects in bridging studies and global multiregional trials / Weichung J. Shih and Hui Quan -- 4. Assessing similarity using the reproducibility and generalizability probabilities and the sensitivity index / Shein-Chung Chow, Ying Lu, and Lan-Yan Yang -- 5. Combining information in clinical drug development : bridging studies and beyond / Kuang-Kuo Gordon Lan and Jos�e Pinheiro -- 6. A Bayesian approach for evaluation of bridging studies / Chin-Fu Hsiao ... [et al.] -- 7. Issues of sample size in bridging trials and global clinical trials / Hsien-Ming James Hung, Sue-Jane Wang, and Robert O'Neill -- 8. Design and sample size considerations for global trials / Christy Chuang-Stein ... [et al.] -- 9. Application of genomic technologies for bridging strategy involving different race and ethnicity in pharmacogenomics clinical trials / Sue-Jane Wang -- 10. Interaction effects in bridging studies / Eric Tsung-Cheng Hsieh and Jen-pei Liu -- 11. Multiregional clinical trials / Yi Tsong and Hsiao-Hui Tsou -- 12. Multiregional clinical trials for global simultaneous drug development in Japan / Kihito Takahashi, Mari Ikuta, and Hiromu Nakajima -- 13. Feasibility and implementation of bridging studies in Taiwan / Mey Wang, Yeong-Liang Lin, and Herng-Der Chern.
520 _a"In recent years, the variations of pharmaceutical products in efficacy and safety among different geographic regions due to ethic factors is a matter of great concern for sponsors as well as for regulatory authorities. However, the key issues lie on when and how to address the geographic variations of efficacy and safety for the product development. To address this issue, a general framework has been provided by the ICH E5 (1998) in a document titled "Ethnic Factors in the Acceptability of Foreign Clinical Data" for evaluation of the impact of ethnic factors on the efficacy, safety, dosage, and dose regimen. The ICH E5 guideline provides regulatory strategies for minimizing duplication of clinical data and requirements for bridging evidence to extrapolate foreign clinical data to a new region. More specifically, the ICH E5 guideline suggests that a bridging study should be conducted in the new region to provide pharmacodynamic or clinical data on efficacy, safety, dosage, and dose regimen to allow extrapolation of the foreign clinical data to the population of the new region. However, a bridging study may require significant development resources and also delay availability of the test medical product to the needed patients in the new region. To accelerate the development process and shorten approval time, the design of multiregional trials incorporates subjects from many countries around the world under the same protocol. After showing the overall efficacy of a drug in all global regions, one can also simultaneously evaluate the possibility of applying the overall trial results to all regions and subsequently support drug registration in each of them"--Provided by publisher.
530 _aAlso available in print edition.
538 _aMode of access: World Wide Web.
650 0 _aDrugs
_xTesting.
655 7 _aElectronic books.
_2lcsh
700 1 _aHsiao, Chin-Fu,
_d1964-
700 1 _aLiu, Jen-pei,
_d1952-
700 1 _aChow, Shein-Chung,
_d1955-
776 1 _z9781439846346 (hardback : alk. paper)
830 0 _aChapman & Hall/CRC biostatistics series (Unnumbered)
856 4 0 _uhttp://marc.crcnetbase.com/isbn/9781439846353
_qapplication/PDF
999 _c12160
_d12159